Transthyretin Cardiac Amyloidosis in Older Americans
- 1 December 2016
- journal article
- review article
- Published by Elsevier in Journal of Cardiac Failure
- Vol. 22 (12) , 996-1003
Abstract
No abstract availableKeywords
This publication has 57 references indexed in Scilit:
- AG10 inhibits amyloidogenesis and cellular toxicity of the familial amyloid cardiomyopathy-associated V122I transthyretinProceedings of the National Academy of Sciences, 2013
- Senile Systemic Amyloidosis: Clinical Features at Presentation and OutcomeJournal of the American Heart Association, 2013
- 99m Tc-Pyrophosphate Scintigraphy for Differentiating Light-Chain Cardiac Amyloidosis From the Transthyretin-Related Familial and Senile Cardiac AmyloidosesCirculation: Cardiovascular Imaging, 2013
- Transthyretin (TTR) Cardiac AmyloidosisCirculation, 2012
- Transthyretin Cardiac Amyloidoses in Older North AmericansJournal of the American Geriatrics Society, 2012
- Left Ventricular Assist Device Therapy in Patients With Restrictive and Hypertrophic CardiomyopathyCirculation: Heart Failure, 2011
- Pressure-Volume Relationships in Patients With Transthyretin (ATTR) Cardiac Amyloidosis Secondary to V122I Mutations and Wild-Type TransthyretinCirculation: Heart Failure, 2011
- Synergy of combined Doxycycline/TUDCA treatment in lowering Transthyretin deposition and associated biomarkers: studies in FAP mouse modelsJournal of Translational Medicine, 2010
- Worsening of congestive heart failure in amyloid heart disease treated by calcium channel-blocking agentsThe American Journal of Cardiology, 1985
- Amyloid cardiomyopathy: Characterization by a distinctive voltage/mass relationThe American Journal of Cardiology, 1982